Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab and failed: HGCSG 1201/OGSG1205.

被引：2
|
作者：
Kawamoto, Yasuyuki
Meguro, Takashi
Yuki, Satoshi
Nakatsumi, Hiroshi
Sasaki, Takahide
Hatanaka, Kazuteru
Uebayashi, Minoru
Iwanaga, Ichiro
Abe, Nobuhiko
Nakamura, Michio
Okuda, Hiroyuki
Eto, Kazunori
Oba, Ayane
Abe, Masakazu
Oba, Koji
Satoh, Taroh
Sakata, Yuh
Sakamoto, Naoya
Komatsu, Yoshito
机构：
[1] Hokkaido Univ Hosp, Dept Canc Ctr, Sapporo, Hokkaido, Japan
[2] Hokkaido Gastroenterol Hosp, Dept Internal Med, Sapporo, Hokkaido, Japan
[3] Hokkaido Univ Hosp, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan
[4] Hokkaido Gastroenterol Hosp, Dept Intenal Med, Sapporo, Hokkaido, Japan
[5] Hakodate Municipal Hosp, Dept Gastroenterol, Hakodate, Hokkaido, Japan
[6] Japanese Red Cross Kitami Hosp, Dept Gastroenterol, Kitami, Hokkaido, Japan
[7] Japanese Red Cross Kitami Hosp, Dept Med Oncol, Kitami, Hokkaido, Japan
[8] Abashiri Kosei Gen Hosp, Dept Gastroenterol, Abashiri, Japan
[9] Sapporo City Gen Hosp, Dept Gastroenterol, Sapporo, Hokkaido, Japan
[10] Keiyukai Sapporo Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan
[11] Tomakomai City Hosp, Dept Gastroenterol, Tomakomai, Japan
[12] Iwamizawa Municipal Gen Hosp, Dept Gastroenterol, Iwamizawa, Japan
[13] Sapporo Kosei Gen Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan
[14] Univ Tokyo, Sch Publ Hlth, Grad Sch Med, Dept Biostat, Tokyo, Japan
[15] Univ Tokyo, Interfac Initiat Informat Studies, Tokyo, Japan
[16] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Osaka, Japan
[17] Misawa City Hosp, Misawa, Japan
[18] Hokkaido Univ Hosp, Ctr Canc, Sapporo, Hokkaido, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.151
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
151
引用
收藏
页数：1
相关论文
共 50 条
  • [1] HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab
    Takahide, Sasaki
    Yasuyuki, Kawamoto
    Satoshi, Yuki
    Takashi, Meguro
    Kazuteru, Hatanaka
    Minoru, Uebayashi
    Ichiro, Iwanaga
    Michio, Nakamura
    Kazunori, Eto
    Hiroyuki, Okuda
    Masakazu, Abe
    Ayane, Oba
    Nobuhiko, Abe
    Atsushi, Sato
    Hiroshi, Nakatsumi
    Kazuaki, Harada
    Tetsuhito, Muranaka
    Masataka, Yagisawa
    Koji, Oba
    Yuh, Sakata
    Yoshito, Komatsu
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab
    Kawamoto, Y.
    Yuki, S.
    Meguro, T.
    Hatanaka, K.
    Uebayashi, M.
    Iwanaga, I.
    Nakamura, M.
    Eto, K.
    Okuda, H.
    Abe, M.
    Aonuma, A.
    Abe, N.
    Sato, A.
    Nakatsumi, H.
    Muranaka, T.
    Yagisawa, M.
    Oba, K.
    Sakata, Y.
    Sakamoto, N.
    Komatsu, Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Meguro, Takashi
    Hatanaka, Kazuteru
    Uebayashi, Minoru
    Nakamura, Michio
    Okuda, Hiroyuki
    Iwanaga, Ichiro
    Kato, Takashi
    Nakano, Shintaro
    Sato, Atsushi
    Harada, Kazuaki
    Oba, Koji
    Sakata, Yuh
    Sakamoto, Naoya
    Komatsu, Yoshito
    ONCOLOGIST, 2022, 27 (05): : 340 - +
  • [4] Phase II study of trastuzumab with irinotecan in HER2-positive gastric cancer previously treated with trastuzumab
    Hatanaka, Kazuteru
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Meguro, Takashi
    Uebayashi, Minoru
    Abe, Masakazu
    Nakamura, Michio
    Okuda, Hiroyuki
    Sakata, Yuh
    Komatsu, Yoshito
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Trastuzumab deruxtecan in previously treated advanced HER2-positive gastric cancer
    Pamuk, Aylin
    Kuetting, Fabian
    Alakus, Hakan
    Bruns, Christiane
    ONKOLOGE, 2021, 27 (01): : 74 - 76
  • [6] Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
    Shitara, Kohei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-Hee
    Sakai, Daisuke
    Chung, Hyun-Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Yamaguchi, Kensei
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25): : 2419 - 2430
  • [7] Trastuzumab In HER2-Positive Metastatic Gastric Cancer
    Croxtall, Jamie D.
    McKeage, Kate
    DRUGS, 2010, 70 (17) : 2259 - 2267
  • [8] The use of trastuzumab in Japanese patients with HER2-positive advanced or metastatic gastric cancer
    Sawaki, A.
    Ohashi, Y.
    Omuro, Y.
    Satoh, T.
    Hamamoto, Y.
    Boku, N.
    Miyata, Y.
    Takiuchi, H.
    Ohtsu, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [9] Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
    Chen, Shang-Chiung
    Kagedal, Matts
    Gao, Yuying
    Wang, Bei
    Harle-Yge, Marie-Laurence
    Girish, Sandhya
    Jin, Jin
    Li, Chunze
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) : 1147 - 1159
  • [10] Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
    Shang-Chiung Chen
    Matts Kagedal
    Yuying Gao
    Bei Wang
    Marie-Laurence Harle-Yge
    Sandhya Girish
    Jin Jin
    Chunze Li
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 1147 - 1159
12345